Yasir Gallero-Salas discusses quantifying alpha-synuclein spread and dopaminergic neuron loss in a model of Parkinson’s using ...
Exidavnemab is being developed as a potential disease-modifying treatment, aiming to halt or slow the progression of ...
Nearly one million people in the U.S. are living with Parkinson’s disease (PD), and this number is expected to grow to 1.2 ...
BioArctic AB (publ), a Swedish research-based biopharma company, announced that the first patient has been dosed with exidavnemab in the EXIST phase 2a study, in Parkinson’s disease patients.
People with Parkinson's who have taken part in drum lessons have seen a "tangible difference" in their mobility, according to ...
Science X is a network of high quality websites with most complete and comprehensive daily coverage of the full sweep of ...
New therapies that are less intrusive but more lasting than current interventions promise to arrest and even reverse neurodegeneration.
A decline in motor skills is a hallmark of Parkinson's disease, regularly taking the form of slowness, rigidity, and tremors.
The company is hoping to show GT-02287 can slow Parkinson's progression by restoring function of GCase, an enzyme encoded by ...
Participant data from three independent studies were evaluated: the Parkinson's Progression Markers Initiative (PPMI), the ...
When Denver artist Tim McKay was diagnosed with Parkinson’s disease last year, he made a quick decision: He would document ...
Exidavnemab is a monoclonal antibody designed to target aggregated forms of the protein α-synuclein, believed to play a role in the disease progression in different neurological disorders including ...